JY
RYTM icon

Jeff Yass’s Rhythm Pharmaceuticals RYTM Stock Holding History

Jeff Yass’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.36M Buy
48,300
+34,800
+258% +$3.15M ﹤0.01% 4475
2026
Q1 		$1.17M Sell
13,500
-4,500
-25% -$438K ﹤0.01% 7469
2025
Q4 		$1.93M Sell
18,000
-91,700
-84% -$9.73M ﹤0.01% 5741
2025
Q3 		$11.1M Sell
109,700
-23,800
-18% -$2.21M ﹤0.01% 2909
2025
Q2 		$8.44M Buy
133,500
+111,200
+499% +$6.81M ﹤0.01% 3087
2025
Q1 		$1.18M Buy
22,300
+6,300
+39% +$350K ﹤0.01% 6836
2024
Q4 		$896K Sell
16,000
-21,600
-57% -$1.19M ﹤0.01% 7244
2024
Q3 		$1.97M Buy
37,600
+10,900
+41% +$522K ﹤0.01% 5297
2024
Q2 		$1.1M Sell
26,700
-16,800
-39% -$671K ﹤0.01% 6362
2024
Q1 		$1.88M Buy
43,500
+16,900
+64% +$740K ﹤0.01% 5482
2023
Q4 		$1.22M Buy
26,600
+17,700
+199% +$558K ﹤0.01% 6489
2023
Q3 		$204K Buy
+8,900
New +$199K ﹤0.01% 10184
2023
Q2 		– Sell
-48,500
Closed -$865K – 12997
2023
Q1 		$865K Buy
48,500
+8,800
+22% +$221K ﹤0.01% 7199
2022
Q4 		$1.16M Sell
39,700
-62,400
-61% -$1.6M ﹤0.01% 5854
2022
Q3 		$2.5M Buy
+102,100
New +$1.9M ﹤0.01% 4460
2022
Q2 		– Sell
-15,700
Closed -$181K – 13813
2022
Q1 		$181K Buy
+15,700
New +$138K ﹤0.01% 11359
2021
Q3 		– Sell
-12,700
Closed -$249K – 13454
2021
Q2 		$249K Sell
12,700
-19,500
-61% -$405K ﹤0.01% 11153
2021
Q1 		$685K Sell
32,200
-115,200
-78% -$3.34M ﹤0.01% 8724
2020
Q4 		$4.38M Buy
147,400
+90,700
+160% +$2.31M ﹤0.01% 3635
2020
Q3 		$1.23M Buy
+56,700
New +$1.3M ﹤0.01% 5622

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Jeff Yass's RYTM Position: Q2 2026 in Review

Jeff Yass reduced its Rhythm Pharmaceuticals (RYTM) stake by 91% in Q2 2026, selling an estimated $4.2M and leaving 4,372 shares worth $485K. The position accounts for ﹤0.01% of the portfolio, ranked #9990.

Jeff Yass first reported a position in RYTM in Q2 2019 and has held it in 28 quarters since. The position peaked at $20.2M in Q4 2022. 301 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Jeff Yass held 4,372 shares of Rhythm Pharmaceuticals worth $485K as of Q2 2026.
  • Jeff Yass sold 46,412 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $4.2M.
  • Rhythm Pharmaceuticals made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #9990 holding.
  • Jeff Yass first reported a position in Rhythm Pharmaceuticals in Q2 2019 and has held it in 28 quarters since.
  • Jeff Yass's Rhythm Pharmaceuticals position peaked at $20.2M in Q4 2022.
  • 301 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.